Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

ISM2196 is a novel, potent WRN inhibitor, designed with the assistance of Alchemistry, one of the latest modules of Chemistry 42. CAMBRIDGE, Mass., September 11, 2024--- Insilico Medicine(“Insilico”), ...

Scientists from Zhejiang University have developed a novel delivery vehicle for CRISPR-Cas9 that is more effective than lipid nanoparticles (LNPs) in treating lung cancer. Rapid liquid nitrogen ...

Researchers from Tango Therapeutics Inc. have unveiled DNA ligase 1 (LIG1) as a potential new therapeutic target for synthetic lethality in BRCA1-mutant cancers after CRISPR/Cas9 screening.

Werner syndrome ATP-dependent helicase (WRN) is an enzyme involved in DNA replication and repair and has been identified as a synthetic lethality target in tumors with high microsatellite instability ...

Repare Therapeutics has three cancer drug candidates in the clinic and another one expected to enter Phase 1 by the end of this year. The biotech aims to ensure it has enough cash to support these ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing ...

ISM2196 is a novel, potent WRN inhibitor, designed with the assistance of Alchemistry, one of the latest modules of Chemistry 42. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy ...